Myeloproliferative Neoplasms including Chronic Myeloid Leukemia
Description
Upon viewing this session, you will be able to:
• MPN: Examine the considerations in choosing a front-line therapy for ET and PV, review non-JAK inhibitor therapies for MF
• identify new treatments for CNL, aCML, myeloid/lymphoid neoplasms with rearrangement of FGFR1, and CALR-mutated MPN
CML: Compare outcomes from front-line dasatinib vs imatinib in CML
• recognize the consequences of BCR-ABL1 TKI discontinuation in CML and identify a novel BCR-ABL1 inhibitor for CML patients with T315I mutation
• MPN: Examine the considerations in choosing a front-line therapy for ET and PV, review non-JAK inhibitor therapies for MF
• identify new treatments for CNL, aCML, myeloid/lymphoid neoplasms with rearrangement of FGFR1, and CALR-mutated MPN
CML: Compare outcomes from front-line dasatinib vs imatinib in CML
• recognize the consequences of BCR-ABL1 TKI discontinuation in CML and identify a novel BCR-ABL1 inhibitor for CML patients with T315I mutation
Presenters
- Aaron Gerds
Pricing
| Member Type | Price |
|---|---|
| List Price | $30.00 |
| Active, International, Emeritus, and Honorary Members | $20.00 |
| Associate, International Associate, Student, and Resident Members | $20.00 |
ASH Meeting on Hematologic Malignancies
Hear the latest developments in clinical care, and get answers to your most challenging patient care questions.
Learn more
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
Copyright © 2021 by American Society of Hematology